Navigation Links
PharmSource Introduces Proprietary Resource for Identifying New Business Opportunities in Bio/Pharma
Date:11/24/2008

PharmSource Lead Sheet upgrades database resources to help companies serving biotech/pharma industry to find new business opportunities and market intelligence.

Springfield, VA (PRWEB) November 24, 2008 -- In response to challenging economic times, PharmSource Information Services, Inc. (PharmSource) announces the expansion of its PharmSource Lead Sheet, a weekly web-based service that reports new business opportunities and market intelligence information to companies that serve the biotechnology/pharmaceutical industry.

The newest capability, known as the Qualifying Information Search, enables detailed database searches for biotech/pharma companies world-wide, based on criteria including: company ownership status (public/private), number of employees, annual R&D expenditure amounts, annual revenue amounts, venture capital sources and geographic locations. Search results are delivered via a downloaded spreadsheet. This robust new feature allows users to quickly qualify and manage prospects directly from their desktops, enabling a highly streamlined and effective lead management process.

About the PharmSource Lead Sheet
PharmSource's scientific research team identifies and qualifies new opportunities in the drug development pipeline, including product status changes and bio/pharma alliances and financings. This information signals new opportunities for contract manufacturers and other biotech/pharma vendors. The Lead Sheet electronically delivers up to 70+ new, global business opportunities each week. Available by annual subscription, PharmSource currently offers a complimentary trial of the PharmSource Lead Sheet to qualified companies.

About PharmSource
PharmSource Information Services, Inc. is a respected provider of business intelligence on contract drug development and manufacture. PharmSource assists biotechnology and pharmaceutical companies in implementing
'/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Sigma-Aldrich Introduces MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA, a Superior Quality siRNA Designed for RNAi Research in Animal Models
2. Bio-Tec Environmental Introduces Their New Plastic Additive Showing 45% Biodegradation of Plastics in Just 14 Days
3. LI-COR Introduces Three IRDye(R) Near-Infrared Fluorescence Resonance Energy Transfer (NIR-FRET) Protease Substrates
4. Sigma-Aldrich Introduces Methylated DNA Quantification Technology for Epigenetic Research
5. PEAK Surgical Introduces PlasmaBlade(TM) Product Line Extensions for Use in General Surgery
6. Contour Products Introduces Groundbreaking Sleep Apnea, Respiratory and Ergonomic Body Comfort Pillows at Medtrade; Self-Explanatory Products Serve Customer Needs, Expand Retailers DME Offerings
7. Nanoscience Instruments, Inc. Introduces All-Diamond AFM Probes
8. China Biologic Products Enters Into Agreement to Acquire 35% Interest in Xian Huitian Blood Products Co., Ltd. and Introduces Preliminary Guidance for 2009
9. LI-COR Introduces the Odyssey(R) Two-Color NIR Fluorescent Protein Molecular Weight Marker
10. SoluLinK Introduces New One-Shot ChromaLink(TM) Biotin Antibody Labeling Kit with Built-in Biotin Quantification.
11. World Leader in Bench Top Flow Chemistry Instruments ThalesNano, Inc. Introduces an Industry First Seminar Series
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):New engineering institute to modify, develop technology for the global poor 2New engineering institute to modify, develop technology for the global poor 3Synthetic protein mimics structure, function of metalloprotein in nature 2Penn, Georgia collaboration awarded $14.6 million to expand pathogen database 2Penn, Georgia collaboration awarded $14.6 million to expand pathogen database 3Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 1Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 2Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 3Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 4Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 5Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 6Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 7Study Links Epilepsy to Brain Protein 57562 1Long time QHR Hospital Client Cary Medical Center Recognized with Top Leadership Team Award 57558 1Long time QHR Hospital Client Cary Medical Center Recognized with Top Leadership Team Award 57558 2Long time QHR Hospital Client Cary Medical Center Recognized with Top Leadership Team Award 57558 3Long time QHR Hospital Client Cary Medical Center Recognized with Top Leadership Team Award 57558 4